Get the Stockscreener App
0.00
100.00%
-5.34
Generation Bio Co stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
See More
Previous Close:
$5.34
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$35.98M
Revenue:
$15.27M
Net Income/Loss:
$-62.63M
P/E Ratio:
0.00
EPS:
-7.3629
Net Cash Flow:
$-114.74M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$6.95
Generation Bio Co Stock (GBIO) Company Profile
Name
Generation Bio Co
Sector
Industry
Phone
857-529-5908
Address
301 BINNEY STREET, CAMBRIDGE
Compare GBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GBIO
Generation Bio Co
|
0.00 | 35.98M | 15.27M | -62.63M | -114.74M | -7.3629 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Generation Bio Co Stock (GBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-25 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-25 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-13-25 | Downgrade | Wedbush | Outperform → Neutral |
| Oct-19-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Nov-08-22 | Initiated | Canaccord Genuity | Buy |
| Dec-14-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-08-21 | Initiated | JMP Securities | Mkt Outperform |
| Feb-24-21 | Initiated | William Blair | Outperform |
| Feb-18-21 | Initiated | Needham | Buy |
| Jul-07-20 | Initiated | Cowen | Outperform |
| Jul-07-20 | Initiated | JP Morgan | Overweight |
| Jul-07-20 | Initiated | Jefferies | Buy |
| Jul-07-20 | Initiated | Wedbush | Outperform |
View All
Generation Bio Co Stock (GBIO) Latest News
Generation Bio Co (GBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Generation Bio Co (GBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Generation Bio Co (GBIO) Institutional Confidence - TradingKey
Generation Bio Co (GBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Generation Bio Co (GBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Generation Bio Co (GBIO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Generation Bio Co (GBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Generation Bio Co (GBIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
One photon, two reactionsnew catalyst converts CO₂ and biowaste simultaneously - EurekAlert!
One Photon, Two ReactionsNew Catalyst Converts CO2 and Biowaste Simultaneously - AZoM
NOROO Holdings Advances Commercialization of Bio-Based 3-HP Through Major Korean Government Initiative - 巴士的報
K-Bio Highlights Next-Generation Obesity and Metabolic Disease Drug Achievements at ADA in the US - 아시아경제
Yeoncheon Green Bio Companies Demonstrate Technological Capabilities and Growth Potential at Seoul K-Bio Week - 아시아경제
CG Bio and CG Medtech Present Next-Generation Spinal Treatment Strategy at GSC 2026 - 아시아경제
Samsung widens bet on next-generation biotech - 매일경제
Samsung will create the "Samsung Life Science Fund No. 3" worth 200 billion won to expand investment.. - 매일경제
Howl Bio is speeding up its efforts to target the biopharmaceutical market at home and abroad with a.. - 매일경제
Massive Bio Announces Next-Generation Reticulum Nexus™ Product Suite at ASCO 2026 - The National Law Review
Samsung Epis Holdings opens China R&D hub to boost ADC drug developmentCHOSUNBIZ - Chosunbiz
Generation Bio Co stock (US37148B1061): Eli Lilly deal fuels fresh attention on DNA-delivery special - AD HOC NEWS
Generation Bio stock (US37148B1061): Trial momentum keeps investors watching - AD HOC NEWS
Generation Bio stock: Trial momentum keeps investors watching - AD HOC NEWS
Organic wastes to next-generation bioplastics through intelligent biomanufacturing of polyhydroxyalkanoates - Nature
Cosmax China unveils next-generation bio beauty solutions at China Expo - theinvestor.co.kr
Atlas Venture amends 13G/A on GBIO holdings (GBIO) - Stock Titan
TradingKey - TradingKey
SNU professor Sangwoo Seo’s research team develops next-generation CRISPR biocontainment technology for controlling microbial survival without DNA cleavage - EurekAlert!
ParcelBio Launches with $13 Million in Financing to Advance Next-Generation mRNA Medicines - Business Wire
Samsung Bioepis announced on the 29th that it will sign a memorandum of understanding (MOU) with the.. - 매일경제
XOMA (XOMA) closes Generation Bio acquisition, details cash-plus-CVR terms and LNP assets - Stock Titan
Generation Bio Co. (GBIO) Reports Q1 Loss, Tops Revenue Estimates - MSN
Firm secures £100k to develop next generation plastics - The Argus
Low-energy path to bioplastics emerges from discarded wood - The Korea Times
Eli Lilly acquires Houston biotech startup for $300M - Houston Chronicle
CrossBridge Bio Enters an Agreement to be Acquired by Eli Lilly to Advance Next-Generation Dual-Payload Antibody-Drug Conjugates - Business Wire
National Growth Fund Invests in SK Bioscience… Supporting Next-Generation Bio and Vaccine Development - Seoul Economic Daily
From Colossal to Chickens: The Scientists Behind Neion Bio’s Biologics Platform - Genetic Engineering and Biotechnology News
Retail Trends: Why is Generation Bio Co stock going downQuarterly Profit Summary & Safe Entry Momentum Stock Tips - baoquankhu1.vn
GBIO SEC FilingsGeneration Bio Co. 10-K, 10-Q, 8-K Forms - Stock Titan
Fed Meeting: Will Generation Bio Co benefit from AI trends2026 Rallies & Expert-Curated Trade Recommendations - baoquankhu1.vn
Sell Signal: Will Generation Bio Co benefit from AI trends2026 Analyst Calls & Smart Investment Allocation Tips - baoquankhu1.vn
Generation Bio Co stock: Why this gene therapy innovator merits your watchlist now - AD HOC NEWS
XOMA SEC FilingsXOMA Royalty Corporation 10-K, 10-Q, 8-K Forms - Stock Titan
Daito Trust Construction to merge two companies involved in biomass power generation into DAITO BIO ENERGY - kentaku.co.jp
Investment Report: Whats the beta of Generation Bio Co stock2026 Geopolitical Influence & AI Driven Price Forecasts - baoquankhu1.vn
Patient-derived ependymoma and medulloblastoma tumoroids: generation, biobanking and drug screening - Nature
King's researchers secure funding to advance next generation bioimaging - King's College London
If You Invested $1,000 in Generation Bio Co. (GBIO) - Stock Titan
Wedbush Downgrades Generation Bio (GBIO) - MSN
Aug Spikes: Whats the beta of Generation Bio Co stockWeekly Loss Report & Safe Entry Point Identification - baoquankhu1.vn
Jefferies downgrades Generation Bio (GBIO) - MSN
Generation Bio Co Stock (GBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):